AZN · Intrinsic value
Is AstraZeneca PLC (AZN) overvalued or undervalued?
AstraZeneca PLC (AZN) trades at the delayed market price of $165.41 a share. That price already implies revenue growth of 8.4% a year for 5 years. TickerWorth's fair value is $154.95 a share (priced within our range of $81.38 – $223.73). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is AZN fairly valued?
- Fair value
- $154.95
- Market price
- $165.41
- Downside to fair value
- 6.3%
- Verdict
- Priced within our range of $81.38 – $223.73
Reverse DCF: Today's price implies revenue growth of 8.4% a year for 5 years; our model assumes 7.5% a year on average over the same horizon.
What is AZN's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: balance sheet looks stretched.
- Value · 52 of 100
Cheaper than 52% of Healthcare companies in US
- Price vs worth · 45 of 100
- Quality · 80 of 100
More profitable than 80% of Healthcare companies in US
- Financial health · 34 of 100
Financially stronger than 34% of Healthcare companies in US
- Growth · 46 of 100
Growing faster than 46% of Healthcare companies in US
- Momentum · 35 of 100
Outperformed 35% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
AZN DCF valuation, input by input
TickerWorth's fair value for AstraZeneca PLC (AZN) is $154.95 a share, against the delayed market price of $165.41 (priced within our range of $81.38 – $223.73). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values AZN at about $163.57 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts AstraZeneca PLC's projected free cash flows at a weighted-average cost of capital (WACC) of 6.9%, with a long-run terminal growth rate of 2.5%. About 81% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 8.4% annual revenue growth for AZN. Our base case instead compounds to about 7.5% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, AZN's modeled DCF value ranges from about $102.78 to $382.79 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what AstraZeneca PLC would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of AZN's intrinsic value. Figures update as new filings and prices come in.
Every input behind AZN's DCF
| Input | Value |
|---|---|
| Base-year revenueASTRAZENECA PLC FY2025 20-F (accession 0001104659-26-019130): ifrs-full:Revenue, FY2025 full year. | $58,739,000,000 |
| Base EBIT marginASTRAZENECA PLC FY2025 20-F (accession 0001104659-26-019130): ifrs-full:ProfitLossFromOperatingActivities 13,743,000,000 / revenue 58,739,000,000 = 23.40%, FY2025. | 23.4% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 11% → 9% → 8% → 6% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.40 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesASTRAZENECA PLC FY2025 20-F (accession 0001104659-26-019130): WeightedAverageShares = 1,550,000,000 shares, FY2025. | 1,550M |
| Market priceBackup price feed · as of 2026-10-19 12:42 UTC | $165.41 |
Change AZN's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does AstraZeneca PLC do?
What does it do?
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in United Kingdom. The company employs roughly 96,100 people.
How does it make money?
The business turns $61.4B in annual revenue into profit. Out of every $100 of sales, about $23 is left as operating profit (operating margin of 23.5%), after a 82% gross margin on the products/services it sells. After all costs, taxes and interest, 17.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries modest debt (0.6× equity), may struggle to cover its short-term bills (0.9× current ratio), and is currently profitable.
Who at AZN filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Sharma Mani | See remarks | Grant / award | $319.60 | Form 4 for Sharma Mani (opens sec.gov in a new tab) | |
| Sharma Mani | See Remarks | Grant / award | $162.60 | Form 4 for Sharma Mani (opens sec.gov in a new tab) | |
| Sharma Mani | See Remarks | Open-market buy | $3,248.81 | Form 4 for Sharma Mani (opens sec.gov in a new tab) | |
| Sharma Mani | SVP, Group Controller | Grant / award | $326.68 | Form 4 for Sharma Mani (opens sec.gov in a new tab) | |
| Sharma Mani | See Remarks | Grant / award | $380.86 | Form 4 for Sharma Mani (opens sec.gov in a new tab) | |
| Sharma Mani | See Remarks | Grant / award | $179.75 | Form 4 for Sharma Mani (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is AZN's intrinsic value?
TickerWorth's blended fair value for AstraZeneca PLC (AZN) is $154.95 per share, versus a market price of $165.41 (priced within our range of $81.38 – $223.73).
Is AZN overvalued or undervalued?
Priced within our range of $81.38 – $223.73 at $165.41. We don't call AZN overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for AZN?
A WACC of 6.9% and a terminal growth rate of 2.5%.
Is AstraZeneca stock undervalued?
TickerWorth's fair value for AstraZeneca PLC (AZN) is $154.95 against a market price of $165.41. Our read: Priced within our range of $81.38 – $223.73. This is a model estimate, not investment advice.
AstraZeneca (AZN) DCF valuation and fair value
Our fair value for AstraZeneca PLC (AZN) is $154.95, built on a 6.9% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into AstraZeneca stock?
Today's price implies revenue growth of 8.4% a year for 5 years; our model assumes 7.5% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $165.41. A model estimate, not investment advice.
AstraZeneca (AZN) insider trading
The most recent insider filing (SEC Form 4) for AstraZeneca PLC (AZN): Sharma Mani, See remarks, grant / award on 2026-10-06. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.